PharmaDIA - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 259,896 | 435,046 | 385,552 | 858,966 | 461,298 | 489,758 | 1,705,225 | 1,738,089 |
| Profit before tax | 49,254 | - | 61,297 | 200,828 | 39,557 | 43,559 | 220,800 | 296,640 |
| Net profit | 46,740 | 57,702 | 50,924 | 170,090 | 32,261 | 36,821 | 185,054 | 248,048 |
| Equity | 52,225 | 84,545 | 132,851 | 271,261 | 183,332 | 136,613 | 294,338 | 418,615 |
| Liabilities | 72,345 | 91,409 | 91,245 | 77,952 | 51,762 | 162,030 | 307,455 | 312,030 |
| Non-current assets | 4,287 | 7,950 | 7,394 | 26,410 | 22,258 | 16,319 | 11,043 | 34,115 |
| Current assets | 120,283 | 168,004 | 216,702 | 322,803 | 212,836 | 282,324 | 590,750 | 696,530 |
| Total assets | 124,570 | 175,954 | 224,096 | 349,213 | 235,094 | 298,643 | 601,793 | 730,645 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 50,268 | 96,303 | 128,050 |
| Social insurance contributions | - | - | - | - | - | 12,487 | 17,887 | 19,497 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +388.0% | +67.4% | -11.4% | +122.8% | -46.3% | +6.2% | +248.2% | +1.9% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 37.5% | 32.8% | 22.7% | 48.7% | 13.7% | 12.3% | 30.8% | 33.9% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 89.5% | 68.3% | 38.3% | 62.7% | 17.6% | 27.0% | 62.9% | 59.3% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 18.0% | 13.3% | 13.2% | 19.8% | 7.0% | 7.5% | 10.9% | 14.3% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 19.0% | - | 15.9% | 23.4% | 8.6% | 8.9% | 12.9% | 17.1% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 1.4 | 1.1 | 0.7 | 0.3 | 0.3 | 1.2 | 1.0 | 0.7 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 97,460 | 145,015 | 88,974 | 210,361 | 117,777 | 122,440 | 426,306 | 425,658 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
PharmaDIA - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2025-03-03 | 2025-03-03 | 1564.70 |
| 2025-02-18 | 2025-02-26 | 1564.70 |
PharmaDIA - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-08-07 | 2026-08-23 | 33.45 |
| 2026-07-01 | 2026-07-07 | 0.49 |
| 2026-04-13 | 2026-04-13 | 164.3 |
| 2026-04-07 | 2026-04-12 | 163.26 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
PharmaDIA, UAB (code 304052894) is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In 2025, the company generated EUR 1.74 million in revenue, up 1.9% year on year, while net profit increased to EUR 248.0 thousand, lifting the profit margin to 14.3%. Over the past three years, the business has shown a strong upward trajectory: revenue rose from EUR 489.8 thousand in 2023 to EUR 1.71 million in 2024 and EUR 1.74 million in 2025, while net profit increased from EUR 36.8 thousand to EUR 185.1 thousand and then to EUR 248.0 thousand. The balance sheet also expanded, with total assets reaching EUR 730.6 thousand in 2025, compared with EUR 601.8 thousand in 2024 and EUR 298.6 thousand in 2023. Equity stood at EUR 418.6 thousand and liabilities at EUR 312.0 thousand, resulting in an equity ratio of 57.3% and debt-to-equity of 0.75. Profitability and efficiency remained strong, with ROE of 59.2%, ROA of 34.0%, and asset turnover of 2.38x. Revenue per employee was EUR 434.5 thousand.